Literatur
-
1 The Diabetes Prevention Program: baseline characteristics of the randomized cohort. The Diabetes Prevention Program Research Group. Diabetes Care 2000 23: 1619-1629
-
2
Eriksson J, Lindström J, Valle T. et al .
on behalf of the Finnish Diabetes Prevention Study Group. Prevention of Type II diabetes in subjects with impaired glucose tolerance: the Diabetes Prevention Study (DPS) in Finland.
Diabetologia.
1999;
42
793-801
-
3
Drucker D J, Nauck M A.
The incretin system: glucagon-like peptide-l receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes.
Lancet.
2006;
368
1696-1705
-
4
Holstein A. et al .
Lower incidence of severe hypoglycemia in type 2 diabetic patients treated with glimepiride versus glibenclamide.
Diabetologia.
2000;
43(Suppl.)
A 40 abs. 157
-
5 Mehnert H. Typ-2-Diabetes. 4. Aufl München; Medikon 2005
-
6
Janka H U, Plewe G, Riddle M C. et al .
Comparison of basal insulin added to oral agents versus twice-daily premixed insulin as initial insulin therapy for type 2 diabetes.
Diabetes Care.
2005;
28
254-259
Prof. Dr. Hellmut Mehnert
Forschergruppe Diabetes e. V.
Drosselweg 16
82152 Krailling
